Nausea and vomiting in advanced cancer

British Medical Bulletin

Volumn 96, Issue 1, 2010, Pages 175-185

  Harris, Dylan G ^a  

^a Hamad Medical Coorporation Doha Qatar   (United Kingdom)

Author keywords

cancer; emesis; nausea; vomiting

Indexed keywords

4 AMINOBUTYRIC ACID; ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CYCLIZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOMPERIDONE; DRONABINOL; ENDORPHIN; GRANISETRON; HALOPERIDOL; HISTAMINE; LEVOMEPROMAZINE; LEVONANTRADOL; LORAZEPAM; METOCLOPRAMIDE; NABILONE; NEUROTRANSMITTER; OLANZAPINE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; SCOPOLAMINE BUTYL BROMIDE; TROPISETRON;

ACUPUNCTURE; ADVANCED CANCER; ANTICIPATORY NAUSEA AND VOMITING; ANXIETY; BLOOD BRAIN BARRIER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COLITIS; CONSTIPATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ENTEROCHROMAFFIN CELL; EUPHORIA; EVIDENCE BASED PRACTICE; HALLUCINATION; HUMAN; HYPERCALCEMIA; INTESTINE OBSTRUCTION; INTRACRANIAL PRESSURE; LABYRINTHITIS; MEDLINE; PAIN; PALLIATIVE THERAPY; PARANOIA; PATHOPHYSIOLOGY; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; RADIATION COLITIS; REVIEW; SEDATION; SIDE EFFECT; STOMACH EMPTYING; VESTIBULAR NEURONITIS;

ANTIEMETICS; EVIDENCE-BASED MEDICINE; HUMANS; NAUSEA; NEOPLASMS; VOMITING;

EID: 78649656595     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq031     Document Type: Review

References (35)

1. Mannix KA. Palliation of nausea and vomiting. CME Cancer Med 2002;1:18-22.
2. Solano JP, Gomes B, Higginson I. A comparison of symptom prevalence in far adVanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006;31:58-69.
3. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with adVanced cancer. Support Care Cancer 2006;14:348-53.
4. Glare P, Pereira G, Kristjanson LJ et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-adVanced cancer. Support Care Cancer 2004;12:432-40.
5. Davis MP, Walsh D. Treatment of nausea and vomiting in adVanced cancer. Support Care Cancer 2000;8:444-52.
6. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 2009; January 13. pii:2406. http://bestpractice. bmj.com/best-practice/evidence/background/2406.html. (6 September 2010, date last accessed).
7. Glare PA, Dunwoodie D, Clark K et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs 2008;68:2575-90.
8. Naeim A, Dy SM, Lorenz KA et al. Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol 2008;26:3903-10.
9. Twycross R, Wilcock A. Palliative Care Formulary 3. 3rd edn. Nottingham: Palliativedrugs.com Limited, 2007.
10. Twycross R, Back I. Nausea and vomiting in adVanced cancer. Eur J Palliative Care 1998;5:39-44.
11. Wood GJ, Shega JW, Lynch B et al. Management of intractable nausea and vomiting in patients at the end of life: 'I was feeling nauseous all of the time . . . nothing was working'. JAMA 2007;298:1196-207.
12. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43.
13. Mannix KA. Palliation of nausea and vomiting. In: Doyle D, Hanks G, Gherny N, Calman K (eds). Oxford Textbook of Palliative Medicine, 3rd edn. Oxford: Oxford University Press, 2005,459-68.
14. Peroutka SJ, Snyder SH. Anti-emetic: neurotransmitter binding predicts therapeutic actions. Lancet 1982;319:658-9.
15. Ison PJ, Peroutka SJ. Neurotransmitter receptor binding studies predict anti-emetic efficacy and side effects. Cancer Treat Reports 1986;70:637-41.
16. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting: a prospective audit. Palliat Med 2001;15:247-53.
17. Lichter I. Results of antiemetic management in terminal illness. J Palliat Care 1993;9:19-21.
18. Srivastava M, Brito-Dellan N, Davis MP et al. Olanzapine as an antiemetic in refractory nausea and vomiting in adVanced cancer. J Pain Symptom Manage 2003;25:578-82.
19. Critchley P, Plach N, Grantham M et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage 2001;22:631-4.
20. Tramer MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21.
21. Ezzo J, Richardson MA, Vickers A et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006;2:CD002285. DOI: 10.1002/14651858.CD002285.pub2.
22. Eisenchlas JH, Garrigue N, Junin M et al. Low-dose levomepromazine in refractory emesis in adVanced cancer patients: an open-label study. Palliat Med 2005;19:71-5.
23. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in adVanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000;2:CD001219.
24. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-21.
25. Mystakidou K, Befon S, Liossi C et al. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far adVanced cancer. Cancer 1998;83:1214-23.
26. Bartlett N, Koczwara B. Control of nausea and vomiting after chemotherapy: what is the evidence? Intern Med J 2002;32:401-7.
27. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med 2003;6:251-5.
28. Abbrederis K, Lorenzen S, Rothling N et al. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Onkologie 2009;32:30-4.
29. Lee A, Fan LTY. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2009;2:CD003281. DOI: 10.1002/14651858.CD003281.pub3.
30. Jordhoy MS, Kaasa S, Fayers P et al. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med 1999;13:299-310.
31. Sagar C. Evidence of absence. http//en.wikipedia.org/wiki/Evidence-of- absence. (6 September 2010, date last accessed).
32. Bruera E, Belzile M, Neumann C et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of adVanced cancer. J Pain Symptom Manage 2000;19:427-35.
33. Hardy J, Daly S, McQuade B et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 2002;10:231-6.
34. Bruera ED, MacEachern TJ, Spachynski KA et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with adVanced cancer. Cancer 1994;74:3204-11.
35. Wilson J, Plourde JY, Marshall D et al. Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. J Palliat Care 2002;18:84-91.